- Home
- / CSL
CSL
Stock Price
$288.9
2024-10-04
Market Capitalization
$139.9 B
2024-10-04
Revenue
$14.7 B
FY, 2024
CSL Summary
Company Summary
- Overview
- CSL is a biotech company providing life-saving medicines. It develops and delivers biotherapies and influenza vaccines, plasma-derived therapeutics, and other solutions.
- Type
- Public
- Status
- Active
- Founded
- 1916
- HQ
- Parkville, AU | view all locations
- Website
- https://www.csl.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Joy Linton, Chief Financial Officer
Brian McNamee, Chair
LocationsView all
2 locations detected
Parkville, VIC HQ
Australia
45 Poplar Rd
King of Prussia, PA
United States
1020 1st Ave
CSL Financials
Summary Financials
- Revenue (H1, 2025)
- $8.4B
- Gross profit (H1, 2025)
- $5.0B
- Net income (H1, 2025)
- $2.1B
- Cash (H1, 2025)
- $1.5B
- EBIT (H1, 2025)
- $2.8B
- Enterprise value
- $150.3B